E-C Coupling and Ca2+ Regulation atrial myocytes

E-C 耦合和 Ca2 调节心房肌细胞

基本信息

  • 批准号:
    7275423
  • 负责人:
  • 金额:
    $ 9.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-01 至 2008-03-06
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): During excitation-contraction (e-c) coupling Ca2+ release from the sarcoplasmic reticulum (SR) in atrial myocytes differs significantly from ventricular myocytes. Atrial myocytes lack transverse tubules and have two different types of SR, junctional (j-SR) and non-junctional SR (nj-SR). Ca2+ release during e-c coupling is spatially inhomogeneous. Ca2+-induced Ca2+-release (CICR) from j-SR and nj-SR is regulated by distinctly different mechanisms. In atrial myocytes IP3-dependent Ca2+ signalling modulates Ca2+ signaling during e-c coupling and cardiac contractility is regulated by the autonomic nervous system. Beta-adrenergic receptor (betaa-AR) signaling mediates symapathetic regulation of cardiac function through intracellular signaling pathways involving G-proteins, protein kinases, nitric oxide (NO) and Ca2+. Ca2+ alternans reflects the alternations of the Ca2+ transient amplitude at regular pacing frequency which results in electromechanical alternans. Atrial Ca2+ alternans are directly related to the generation of atrial arrhythmias which is a major contributor to cardiovascular morbidity and mortality. The overall goal of the proposed study is to elucidate mechanisms and signalling pathways that are relevant to normal atrial e-c coupling and their perturbations which lead to Ca2+ alternans and therefore arrhythmogenic behavior in atrial tissue. The following Specific Aims are proposed: Specific Aim #1: Determine the subcellular mechanisms by which inositol-phosphate (IP3) signaling governs Ca2+ signaling during e-c coupling. Specific Aim #2. Determine the mechanisms by which a-adrenergic signaling regulates Ca2+ release from j-SR and nj-SR during e-c coupling. Specific Aim #3. Elucidate the mechanisms through which disturbance(s) of IP3-, a-AR- and NO-dependent signaling leads to Ca2+ aiternans. To achieve these aims a multitude of experimental techniques will be used: high resolution [Ca2+]i imaging by laser scanning confocal microscopy in single atrial myocytes, whole-cell voltage clamp techniques to study membrane currents, single channel recordings through cardiac SR Ca2+ release channels reconstituted into planar lipid bilayers, subcellular photolysisof caged Ca2+ and IP3, and pharmacological manipulation of a-adrenergic regulation, IP3 signaling and Ca2+ entry, release and uptake. The proposed research will provide fundamental new information on the regulation of atrial e-c coupling and Ca2+ release under normal and altered conditions relevant to atrial arrhythmias.
描述(由申请人提供):在兴奋 - 收缩(E-C)耦合Ca2+在心肌细胞中的肌质网(SR)释放的Ca2+释放与心肌细胞中的描述与心肌细胞中的核细胞(SR)释放。心肌细胞缺乏横向小管,并且具有两种不同类型的SR,连接(J-SR)和非官方SR(NJ-SR)。 E-C耦合期间的Ca2+释放在空间上是不均匀的。来自J-SR和NJ-SR的Ca2+诱导的Ca2+弹药(CICR)受到明显不同的机制的调节。在心肌细胞中,依赖IP3的Ca2+信号传导调节E-C耦合过程中的Ca2+信号传导和心脏收缩率在自主神经系统中调节。 β-肾上腺素能受体(betaa-ar)信号传导通过涉及G蛋白,蛋白激酶,一氧化氮(NO)和Ca2+的细胞内信号传导途径介导心脏功能的对立调节。 Ca2+替代品反映了在常规起搏频率下Ca2+瞬态幅度的交替,从而导致机电替代品。心房CA2+替代品与心房心律不齐的产生直接相关,这是导致心血管发病率和死亡率的主要因素。拟议研究的总体目标是阐明与正常心房E-E-C耦合及其扰动有关的机制和信号传导途径,这些机制导致Ca2+替代品,因此在心房组织中的心律失常行为。提出了以下具体目标: 具体目标#1:确定肌醇 - 磷酸(IP3)信号传导在E-C耦合过程中控制CA2+信号传导的亚细胞机制。 特定目标#2。确定A-肾上腺素能信号在E-C耦合过程中调节J-SR和NJ-SR释放Ca2+的机制。 特定目标#3。阐明IP3-,A-AR-和NO依赖性信号的扰动导致Ca2+ Aiternans的机制。 To achieve these aims a multitude of experimental techniques will be used: high resolution [Ca2+]i imaging by laser scanning confocal microscopy in single atrial myocytes, whole-cell voltage clamp techniques to study membrane currents, single channel recordings through cardiac SR Ca2+ release channels reconstituted into planar lipid bilayers, subcellular photolysisof caged Ca2+ and IP3以及A-肾上腺素能调节,IP3信号传导和CA2+输入,释放和摄取的药理操作。 拟议的研究将提供有关在正常和改变与心房心律失常有关的正常和改变的条件下对心房E-C耦合调节和Ca2+释放的基本新信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LOTHAR A BLATTER其他文献

LOTHAR A BLATTER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LOTHAR A BLATTER', 18)}}的其他基金

Atrial Excitation-Contraction Coupling, Calcium Signaling and Electro-Mechanical Alternans
心房兴奋-收缩耦合、钙信号传导和机电交替
  • 批准号:
    10667610
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
IP3 receptor, NOX2 and calcium signaling domains in atrial physiology and pathophysiology
心房生理学和病理生理学中的 IP3 受体、NOX2 和钙信号传导域
  • 批准号:
    10443403
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
IP3 receptor, NOX2 and calcium signaling domains in atrial physiology and pathophysiology
心房生理学和病理生理学中的 IP3 受体、NOX2 和钙信号传导域
  • 批准号:
    10597225
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
Pathophysiological Regulation of Atrial Alternans and Atrial Fibrillation
心房交替和心房颤动的病理生理调节
  • 批准号:
    9907864
  • 财政年份:
    2017
  • 资助金额:
    $ 9.92万
  • 项目类别:
Pathophysiological Regulation of Atrial Myocyte Excitation-Contraction Coupling and Calcium Signaling
心房肌细胞兴奋-收缩耦合和钙信号传导的病理生理调节
  • 批准号:
    9924276
  • 财政年份:
    2017
  • 资助金额:
    $ 9.92万
  • 项目类别:
MItochondrial Dysfunction in Cardiac Hypertrophy and Failure
心脏肥大和衰竭中的线粒体功能障碍
  • 批准号:
    7847834
  • 财政年份:
    2010
  • 资助金额:
    $ 9.92万
  • 项目类别:
MItochondrial Dysfunction in Cardiac Hypertrophy and Failure
心脏肥大和衰竭中的线粒体功能障碍
  • 批准号:
    8244422
  • 财政年份:
    2010
  • 资助金额:
    $ 9.92万
  • 项目类别:
MItochondrial Dysfunction in Cardiac Hypertrophy and Failure
心脏肥大和衰竭中的线粒体功能障碍
  • 批准号:
    8064744
  • 财政年份:
    2010
  • 资助金额:
    $ 9.92万
  • 项目类别:
MItochondrial Dysfunction in Cardiac Hypertrophy and Failure
心脏肥大和衰竭中的线粒体功能障碍
  • 批准号:
    8319979
  • 财政年份:
    2010
  • 资助金额:
    $ 9.92万
  • 项目类别:
MItochondrial Dysfunction in Cardiac Hypertrophy and Failure
心脏肥大和衰竭中的线粒体功能障碍
  • 批准号:
    8451323
  • 财政年份:
    2010
  • 资助金额:
    $ 9.92万
  • 项目类别:

相似国自然基金

腺苷酸环化酶ADCY3调控鸡肌内脂肪沉积的作用及机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
腺苷酸环化酶ADCY3调控鸡肌内脂肪沉积的作用及机制研究
  • 批准号:
    32202656
  • 批准年份:
    2022
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
腺苷酸环化酶ZmRPP13-LK3催化生成的cAMP在玉米耐高温胁迫中的作用机制解析
  • 批准号:
    32171945
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
CUL3和ARIH1介导的腺苷酸环化酶异源敏化在吗啡依赖发生中的作用研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    24 万元
  • 项目类别:
    青年科学基金项目
灰霉菌腺苷酸环化酶调节光响应与致病性的机理研究
  • 批准号:
    31972121
  • 批准年份:
    2019
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目

相似海外基金

Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer
(R,S)-MNF作为胰腺癌双靶向疗法的开发
  • 批准号:
    10546773
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
一种治疗阿尔茨海默病的新型 5 型腺苷酸环化酶药理抑制剂
  • 批准号:
    10608477
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
Assay development for characterization of Adrb3 antagonists as pain therapeutics
Adrb3 拮抗剂作为疼痛治疗药物表征的测定方法开发
  • 批准号:
    10287083
  • 财政年份:
    2021
  • 资助金额:
    $ 9.92万
  • 项目类别:
Regulators and interactomes of CaV1.2 in health and disease
CaV1.2 在健康和疾病中的调节因子和相互作用组
  • 批准号:
    10534139
  • 财政年份:
    2020
  • 资助金额:
    $ 9.92万
  • 项目类别:
Macrophage Immunometabolism alteration by intense beta agonist therapy.
强β激动剂治疗改变巨噬细胞免疫代谢。
  • 批准号:
    10472466
  • 财政年份:
    2020
  • 资助金额:
    $ 9.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了